Projects per year
Personal profile
Area of Expertise
The general research area of Dr. Mathew’s laboratory is Cancer Immunology. His research focuses on the Cellular and Molecular Biology of human natural killer (NK) cells and their recognition by cancer cells. NK cells are a subpopulation of lymphocytes that play an important role against cancer and various viral and bacterial infections.
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.
Education/Academic qualification
BS in Physics, University of Kerala
MS in Biochemistry, University of Poona
PhD in Biochemistry, University of Poona
Fingerprint
Dive into the research topics where Porunelloor Mathew is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 13 Finished
-
Exosomal-Annexin A2 Promotes Metastasis in Triple-negative Breast Cancer
1/06/17 → 31/05/18
Project: Research
-
Molecular Characterization of NKp44 Ligand on Astrocytes
National Institute of Neurological Disorders and Stroke
1/02/17 → 31/01/20
Project: Research
-
-
Molecular Characterization of NKp44 Ligand on Astrocytes
NINDS: Neurological Disorders & Stroke
1/02/17 → 31/01/19
Project: Research
-
Role of LLT1 and PCNA as Natural Killer Cell Immune Evasion Strategies of HCT 116 Cells
Malaer, J. D. & Mathew, P. A., Dec 2020, In: Anticancer Research. 40, 12, p. 6613-6621 9 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Roles of nk cell receptors 2b4 (Cd244), cs1 (cd319), and llt1 (clec2d) in cancer
Buller, C. W., Mathew, P. A. & Mathew, S. O., Jul 2020, In: Cancers. 12, 7, p. 1-15 15 p., 1755.Research output: Contribution to journal › Review article › peer-review
Open Access12 Scopus citations -
2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer
Malaer, J. D., Marrufo, A. M. & Mathew, P. A., Jul 2019, In: Clinical Immunology. 204, p. 50-56 7 p.Research output: Contribution to journal › Review article › peer-review
9 Scopus citations -
A novel ligand on astrocytes interacts with natural cytotoxicity receptor NKp44 regulating immune response mediated by NK cells
Bowen, K. E., Mathew, S. O., Borgmann, K., Ghorpade, A. & Mathew, P. A., Feb 2018, In: PLoS ONE. 13, 2, e0193008.Research output: Contribution to journal › Article › peer-review
8 Scopus citations -
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma
Malaer, J. D. & Mathew, P. A., 1 Jan 2017, In: American Journal of Cancer Research. 7, 8, p. 1637-1641 5 p.Research output: Contribution to journal › Review article › peer-review
50 Scopus citations